Intellipharmaceutics Expands Drug Commercialization Expertise

TORONTO, Feb 7, 2011 (GlobeNewswire via COMTEX) --

Intellipharmaceutics International Inc. (Nasdaq: IPCI | PowerRating) (TSX: I | PowerRating) today announced it has retained the services of Doll Consulting, LLC and its principal, David S. Doll, to assist the Company with the commercialization of products in its controlled-release generic drug portfolio and its 505(b)(2) New Drug Application (NDA) portfolio. Mr. Doll has over 26 years of solid pharmaceutical industry experience in commercial operations, including at Impax Laboratories, Inc. from 2006 to 2008 as Executive Vice President, Commercial Operations. Most notably, he successfully negotiated long-term agreements between Impax and several major pharmaceutical companies, including TEVA, Andrx Corporation, Shire US, Inc., DAVA Pharmaceuticals, Schering Corporation, Wyeth, Novarits, Leiner Health Products, Purdue Pharma and Vedco Inc.

"We now have four products filed with the FDA for the purpose of obtaining regulatory approval in the U.S. [ANDA's for Focalin XR(R), Effexor XR(R), Protonix(R), Glucophage XR(R)] and expect to file at a minimum an additional two products this year," stated Dr. Isa Odidi, CEO and co-Founder of Intellipharmaceutics. "Given our progress last year, our anticipated growth moving forward, and an increased focus on partnering due to our advancing pipeline, Dave Doll, with his impressive track record in business development and commercialization, is an excellent addition to our team."

"I am very excited to be part of the impressive growth story that is emerging at Intellipharmaceutics," commented Mr. Doll. "I believe Intellipharmaceutics has exceptional drug formulation and development expertise and given the mature pipeline of products both on the generics side and with the Company's abuse-resistant Rexista(TM) technology platform, the Company has an opportunity to see a number of strategic commercial initiatives come to fruition in the near term."

Prior to establishing Doll Consulting LLC, Mr. Doll served as Executive Vice President, Commercial Operations of Impax from February 2006 to August 2008 and prior to that he served as Senior Vice President, Sales and Marketing from March 2001. From June 1993 to February 2001, Mr. Doll served in a number of management functions at Merck & Co., Inc. including: Senior Director - Managed Care, General Manager - West Point Pharma and Director of Marketing - West Point Pharma. From December 1984 until June 1993, Mr. Doll held a number of sales and marketing management positions at Lemmon Company (subsidiary of Teva Pharmaceutical Industries Ltd.). Mr. Doll has a B.S. in Commerce from Rider University as well as an MBA in Pharmaceutical Marketing from Saint Joseph's University.

About Intellipharmaceutics

Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel or generic controlled release and targeted release oral solid dosage drugs. The Company's patented Hypermatrix(TM) technology is a unique and validated multidimensional controlled-release drug delivery platform that can be applied to the efficient development of a wide range of existing and new pharmaceuticals. Based on this technology, Intellipharmaceutics has a pipeline of products in various stages of development in therapeutic areas that include neurology, cardiovascular, GIT, pain and infection.

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.